Earnings Feed
Start Free
Aligos Therapeutics, Inc.·4

Oct 20, 4:56 PM ET

Quan Lucinda Y. 4

4 · Aligos Therapeutics, Inc. · Filed Oct 20, 2020

Insider Transaction Report

Form 4
Period: 2020-10-20
Aligos Therapeutics, Inc.ALGS
Quan Lucinda Y.
See Remarks
Transactions
  • Conversion

    Common Stock

    [F1][F2]
    2020-10-20+6,835→ 6,835 total(indirect: See footnote)
  • Conversion

    Common Stock

    [F1][F2]
    2020-10-20+1,697→ 8,532 total(indirect: See footnote)
  • Conversion

    Common Stock

    [F1][F2]
    2020-10-20+726→ 9,258 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    [F1][F2]
    2020-10-20−6,835→ 0 total(indirect: See footnote)
    → Common Stock (6,835 underlying)
  • Conversion

    Series B-1 Preferred Stock

    [F1][F2]
    2020-10-20−1,697→ 0 total(indirect: See footnote)
    → Common Stock (1,697 underlying)
  • Conversion

    Series B-2 Preferred Stock

    [F1][F2]
    2020-10-20−726→ 0 total(indirect: See footnote)
    → Common Stock (726 underlying)
Holdings

  • Common Stock

    375,547
Footnotes (2)
  • [F1]Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date.
  • [F2]Lucinda Y. Quan, Trustee of the LYQ Trust, dated August 22, 2010.
Signature
/s/ Lucinda Y. Quan|2020-10-20

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4